Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03942653 · ClinicalTrials.gov registry record · Phase 2
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
A Phase 2 study of Salivary Gland Carcinoma, sponsored by Manish Patel.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT03942653: Recruiting Phase 2 study of Salivary Gland Carcinoma, sponsored by Manish Patel.
NCT03942653 is a Phase 2 study of Salivary Gland Carcinoma that is actively recruiting participants, run by Manish Patel. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03942653, a Phase 2 study of Salivary Gland Carcinoma, is actively recruiting participants, sponsored by Manish Patel.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
Primary Outcome
Objective response rate to therapy (complete and partial responses) at 3 month intervals after beginning goserelin and pembrolizumab based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Goserelin Acetate
Study Locations (7)
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
- University of Illinois Cancer Center - Chicago
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Maryland
- Univeristy of Maryland - Baltimore
Michigan
- University of Michigan Health System - Ann Arbor
Minnesota
- University of Minnesota: Masonic Cancer Center - Minneapolis
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-05-30 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT03942653 shows while recruiting
NCT03942653 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Salivary Gland Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03942653 lists 7 locations in 6 states (Illinois, Iowa, Maryland).
Frequently Asked Questions
What is clinical trial NCT03942653 about?
NCT03942653 is a clinical study titled "Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma". A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
What is the current status of trial NCT03942653?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-05-30. Estimated completion is 2026-08.
What conditions does trial NCT03942653 study?
This clinical trial studies the following conditions: Salivary Gland Carcinoma.
What interventions are being tested in trial NCT03942653?
The interventions under investigation include: Pembrolizumab (DRUG), Goserelin Acetate (DRUG).
Who is sponsoring clinical trial NCT03942653?
This trial is sponsored by Manish Patel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03942653 being conducted?
This trial has 7 study locations across Illinois, Iowa, Maryland, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Salivary Gland Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03942653's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI